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Renal cell carcinomas (RCCs) are known for their unpredictable metastatic pattern. We present the case of a 63-year-old woman
who initially presented in 1992 with a metastasis in the left calcaneus that led to the discovery of RCC. In 1998, a new metastasis
was found in the ovary. In 2008, the diagnosis of a gallbladder metastasis was made. All metastases were surgically removed;
no additional systemic therapies were used. Aggressive surgical treatment can prolong the survival of patients with resectable
metastases. Patterns of metastasis are discussed, and a brief review of the literature is given regarding each localization.
1.Introduction
In 2010 kidney cancer accounted for 4% and 3% of all newly
diagnosed malignancies in men and women,respectively[1].
From 80% to 85% of these cancers are renal cell carcinomas
(RCCs), which are often diagnosed during radiographic
examinations for other purposes. At the time of diagnosis,
approximately one-third of patients present with metastatic
disease. The outcome in patients with metastatic disease is
very poor, with a 5-year survival rate of only 5% to 10%
[2].
2.CaseReport
In 1992, a 47-year-old woman presented with left heel
pain. After further examination, the orthopedic surgeon
identiﬁed a possible malignancy of the calcaneus. After
wedge excision, histopathology identiﬁed the lesion as a
metastasis originating from an RCC (Figure 1). Further
radiographicinvestigationsrevealedRCCintherightkidney.
Adjuvant radiation therapy of the calcaneus and right radical
nephrectomyfollowed.Histopathologyofthekidneyshowed
a tumor of 5cm, consisting of a clear cell adenocarcinoma
F¨ uhrman grade 3. Vascular invasion, but no capsular exten-
sion, was observed (Figure 1).
For the next 5 years, followup showed no recurrences.
Nevertheless, ultrasonography in December 1997 revealed
a large polylobular mass in close connection with the
uterus. Tomography revealed multiple adenopathies and a
ﬁbromyomatous uterus (Figure 2). Hysterectomy, bilateral
ovariectomy, and iliaclymphadenectomy were performed.
Pathologicanalysisshowedauterinemyoma,anegativeright
iliac lymph node, and a clear cell tumor in the left ovary
compatible with an RCC metastasis (Figure 1).
For the next 11 years, radiographic followup was
uneventful.InAugust2008,anabdominalCTscanidentiﬁed
a polypoid lesion in the gallbladder (Figure 3). A laparo-
scopic cholecystectomy was performed. Macroscopic and
microscopic appearances led to the diagnosis of an RCC
metastasis (Figure 1).2 Case Reports in Medicine
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Figure 1:(a)Primaryrenalcellcarcinoma(clearcelltype)inthekidney.Thetumor(t)issharplydemarcatedfromtherenalparenchyma(k).
The tumor consists of sheets of large epithelial cells with an optically empty cytoplasm and sharp cell borders (inset). (original magniﬁcation
25x and 200x (inset); Hematoxylin Eosin stain), (b) Metastasis of clear cell carcinoma in the oscalcaneum. Note the similar cell type in
metastasis and primary tumor (original magniﬁcation 200x; Hematoxylin Eosin stain). (c) Ovarian metastasis of clear cell carcinoma. Note
the similar cell type in metastasis and primary tumor (original magniﬁcation 200x; Hematoxylin Eosin stain). (d) Metastasis of clear cell
carcinoma in the gallbladder. The tumor (t) is located deep in the cholecystic wall (m: mucosa) (original magniﬁcation 25x; Hematoxylin
Eosin stain). Inset: the tumor cells show the typical membranous staining pattern for CD10, consistent with the immunophenotype of a
clear cell RCC (original magniﬁcation 200x; immunohistochemical CD10 stain).
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Figure 2: Contrast-enhanced CT of the pelvis showing a large
myoma on the right side of the uterus. Note the cyst-like lesion in
the left ovarium, without intraluminal nodules (arrow).
3. Discussion
Kidney cancer is one of the most deadly urological tumors.
The5-yearrelativesurvivalrateforallstagesisapproximately
69.5% [3]. At initial diagnosis, one-third of patients present
with metastasis [2]. According to the study of Lam et al.,
eventually, up to 28% of patients with clinically localized
disease develop distant metastatic disease within 5 years [4].
Diagnosis of metastases precedes RCC diagnosis in only 5%
of cases.
The most frequent localizations, in order of frequency,
are the lungs, bones, liver, lymph nodes, adrenals, and brain.
However, RCC metastases have been described in virtually
every organ of the human body [5].
In the case of bone metastases, the spine (80% of
localizations) and the long bones (10%) are most commonly
involved; the distal bones of the hands and feet are very
rarely involved. One study that examined 2800 bone tumors
found only 19 in the foot, of which 11 were metastatic.
The calcaneus is the most frequently aﬀected bone in the
foot, followed by the tarsal bones. Metastases of RCC toCase Reports in Medicine 3
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Figure 3: CT scan showing status after right nephrectomy and an
evolutive papillary lesion in the gallbladder of approximately 1.9cm
((a) and (b), arrows). (b) Contains the coronal reconstruction.
the calcaneus are very rare. They are associated with a poor
prognosis, due to their relationship with diﬀuse metastatic
disease [6, 7].
Kollender et al. concluded that aggressive surgical exci-
sion of RCC bone metastases is justiﬁed for pain relief, local
tumor control, and the prevention of morbidity associated
with pathological fractures. Although the patient population
was rather small, a relatively prolonged survival was shown
[8]. Patients also have a signiﬁcant better survival if a tumor-
freeresectionmargincanbeachieved.Ifacompleteresection
of multiple metastases (even a combination of osseous and
visceral metastases) is technically feasible, 5-year survival
r a t e su pt o4 0 %a r ep o s s i b l e[ 9].
In our case radiotherapy was performedafterthe surgical
excision of the calcaneal metastasis. Despite the general
accepted fact that the renal cell carcinoma is radioresistant,
several study groups have clearly showed a palliative beneﬁt
in symptomatic osseous metastases from these tumors.
None of the mentioned reports investigated possible survival
advantages [10–12].
Ovarian metastases originating from RCC are very rare
and to the best of our knowledge have only been described
in few cases. Valappil et al. listed 12 cases, and Insabato et al.
described another 3 cases. Involvement of the contralateral
ovary is even rarer. In most of the cases, the ovarian
mass was detected after the diagnosis of the renal tumor.
RCC metastases in the ovaries are often misdiagnosed as
primary ovarian clear cell carcinomas, due to the presence
of clear cells in ovary tumors as well as in RCCs. With
immunohistochemical techniques, the ability to diﬀerentiate
between these tumors is improving [13–15].
Gallbladder metastases due to primary RCC are rare.
In the report of Ishizawa, covering a period of more than
50 years, 24 cases have been described. Almost all patients
were men. In the present case, the time interval between
primary tumor and gallbladder tumor is 16 years; only two
authors have reported longer time intervals (27 years in both
cases). In almost all cases, the gallbladder tumor was found
in routine followup, without any associated symptoms.
Followup in this group of 24 patients showed a maximum
tumor-free period of 6 years after cholecystectomy. However,
l a t er e c u r r e n c eo fR C Cc a nn e v e rb ee x c l u d e d[ 16].
In metastatic renal cell carcinoma patients, the use of
molecular targeted therapies that block the VEGF pathway
or the mTOR pathway oﬀers new perspectives. For the
moment, diﬀerent molecules are available, each with their
own eﬃcacy and side eﬀects. Clinical guidelines for the ﬁrst-
and second-line treatment exist, but the real question lies
in the individual treatment of each patient. There is a need
for prognostic factors and biomarkers. Better results may be
achieved by using combination or sequential therapy. And
the search for other pathways and new agents interfering in
these pathways should continue [17].
Severalstudieshaveshownmetastasectomyforresectable
tumors to result in increased survival compared to no
surgery. Especially in the case of lung metastases, 5-year
survival rates of up to 50% have been reported [18]. As
mentioned before, a complete resection of bone metastases
can result in a 5-year survival rate of 40% [9]. Patients
with brain metastases tend to have a poor prognosis,
due to the fact that often other extracranial regions are
involved. Wro´ nski et al. analysed 50 operatively treated
patients, with a median survival of 12.1 months from the
diagnosis of the brain metastases [19]. The biggest series
on metastasectomy for liver metastases from RCC included
31 patients and showed 5-year survival rates of 38.9%
[20]. Molecular targeted therapies may provide a useful
tool in combination with surgical removal of metastases. A
recent study showed the feasibility of this approach with
acceptable morbidity. A longer progression-free survival
couldbereached,butfurtherinvestigationsremainnecessary
[21].4 Case Reports in Medicine
4. Conclusion
Given the poor 5-year survival in patients with metastatic
RCC, it is rather exceptional that our patient is still alive 17
years after the initial RCC diagnosis. This woman has already
presented with diﬀerent metachronous metastases, empha-
sizing the importance of a strict radiographic followup. The
use of radiotherapy in the case of osseous metastases is
reserved for the palliative setting. We do not plead against
the use of targeted therapies, but when technically feasible
surgery should play an important role. Thanks to aggressive
treatment of each metastasis, the life expectancy of our
patient remains higher than the average life expectancy
patients with metastatic RCC would indicate.
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